Although the phenomenon of withdrawal symptoms is well known for some psychotropic drugs, including serotonin selective reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors, reports of withdrawal symptoms following the discontinuation of a noradrenergic and specific serotonergic antidepressant are limited. A case of a female patient who experienced rebound withdrawal after tapering and discontinuing (30 mg) mirtazapine is herein described. The present clinical case supports a growing literature suggesting that withdrawal symptoms might occur after the discontinuation of antidepressants. It highlights the importance of diagnosing withdrawal due to the discontinuation of a noradrenergic and specific serotonergic antidepressant and suggests that such a withdrawal might be treated with a different strategy than reintroducing the drug previously discontinued.
Withdrawal symptoms after discontinuation of a noradrenergic and specific serotonergic antidepressant: A case report and review of the literature / Cosci, Fiammetta. - In: PERSONALIZED MEDICINE IN PSYCHIATRY. - ISSN 2468-1717. - ELETTRONICO. - 1-2:(2017), pp. 81-84. [10.1016/j.pmip.2016.11.001]
Withdrawal symptoms after discontinuation of a noradrenergic and specific serotonergic antidepressant: A case report and review of the literature
COSCI, FIAMMETTA
2017
Abstract
Although the phenomenon of withdrawal symptoms is well known for some psychotropic drugs, including serotonin selective reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors, reports of withdrawal symptoms following the discontinuation of a noradrenergic and specific serotonergic antidepressant are limited. A case of a female patient who experienced rebound withdrawal after tapering and discontinuing (30 mg) mirtazapine is herein described. The present clinical case supports a growing literature suggesting that withdrawal symptoms might occur after the discontinuation of antidepressants. It highlights the importance of diagnosing withdrawal due to the discontinuation of a noradrenergic and specific serotonergic antidepressant and suggests that such a withdrawal might be treated with a different strategy than reintroducing the drug previously discontinued.File | Dimensione | Formato | |
---|---|---|---|
Cosci_2017_withdrawal mirtazapine_Personalized Med Psych.pdf
Accesso chiuso
Descrizione: paper
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
220.93 kB
Formato
Adobe PDF
|
220.93 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.